3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
2
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
Specimen Handling
480
pembrolizumab
455
Magnetic Resonance Spectroscopy
420
Carboplatin
327
Cyclophosphamide
314
Cisplatin
271
Biopsy
271
Radiotherapy
244
Paclitaxel
229
Gemcitabine
227
Bevacizumab
213
Nivolumab
188
fludarabine
185
venetoclax
174
Drug Therapy
170
Blood Specimen Collection
158
Dexamethasone
157
Oxaliplatin
154
Injections
152
Capecitabine
151
Fluorouracil
144
Docetaxel
144
Radiosurgery
137
Standard of Care
135
Rituximab
125
Pemetrexed
117
durvalumab
115
Leucovorin
109
atezolizumab
107
Radiation
106
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Acetic Acid
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled